TrialHuman vaccines & immunotherapeutics2017

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.

Olivier Godeaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.